A functional variant at the miR-214 binding site in the methylenetetrahydrofolatereductase gene alters susceptibility to gastric cancer in a chinese han population

Cellular Physiology and Biochemistry

Volumn 36, Issue 2, 2015, Pages 622-630

  Chen, Qiaoyun ^a   Qin, Rong ^a   Fang, Yue ^a   Li, Hao ^b   Liu, Yangchen ^b  

^a AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b TAIXING PEOPLE'S HOSPITAL   (China)

Author keywords

Gastric cancer; miR 214; MTHFR; Polymorphism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE; MICRORNA 214; 3' UNTRANSLATED REGION; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MICRORNA; MIRN214 MICRORNA, HUMAN;

AGE; ALCOHOL CONSUMPTION; ALLELE; ARTICLE; BINDING SITE; CANCER RISK; CONTROLLED STUDY; FEMALE; GENDER; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAN CHINESE; HELICOBACTER INFECTION; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; IMMUNOBLOTTING; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; STOMACH ADENOCARCINOMA; 3' UNTRANSLATED REGION; AGED; CASE CONTROL STUDY; CHINA; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; STOMACH NEOPLASMS;

3' UNTRANSLATED REGIONS; AGED; BINDING SITES; CASE-CONTROL STUDIES; CHINA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MICRORNAS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; STOMACH NEOPLASMS;

EID: 84929663480     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000430125     Document Type: Article

References (44)

1. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M: Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2005;366:1784-1793.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
3. Cui Y, Chen J, He Z, Xiao Y: SUZ12 depletion suppresses the proliferation of gastric cancer cells. Cell Physiol Biochem 2013;31:778-784.
4. Correa P: Human gastric carcinogenesis: A multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735-6740.
5. Kelley JR, Duggan JM: Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003;56:1-9.
6. Milne AN, Carneiro F, O'Morain C, Offerhaus GJ: Nature meets nurture: molecular genetics of gastric cancer. Hum Genet 2009;126:615-628.
7. Yang L, Liu D, Liang S, Guo R, Zhang Z, Xu H, Yang C, Zhu Y: Janus kinase 2 polymorphisms are associated with risk in patients with gastric cancer in a Chinese population. PLoS One 2013;8:e64628.
8. Wu MS, Chen CJ, Lin JT: Host-environment interactions: their impact on progression from gastric inflammation to carcinogenesis and on development of new approaches to prevent and treat gastric cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1878-1882.
9. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
10. Ambros V: The functions of animal microRNAs. Nature 2004;431:350-355.
11. Zhou X, Xia Y, Su J, Zhang G: Down-regulation of miR-141 induced by helicobacter pylori promotes the invasion of gastric cancer by targeting STAT4. Cell Physiol Biochem 2014;33:1003-1012.
12. Che H, Sun LH, Guo F, Niu HF, Su XL, Bao YN, Fu ZD, Liu HL, Hou X, Yang BF, Ai J: Expression of amyloid-associated miRNAs in both the forebrain cortex and hippocampus of middle-aged rat. Cell Physiol Biochem 2014;33:11-22.
13. Lu J, Clark AG: Impact of microRNA regulation on variation in human gene expression. Genome Res 2012;22:1243-1254.
14. Cheng CK, Kwan TK, Cheung CY, Ng K, Liang P, Cheng SH, Chan NP, Ip RK, Wong RS, Lee V, Li CK, Yip SF, Ng MH: A polymorphism in the 3'-untranslated region of the NPM1 gene causes illegitimate regulation by microRNA-337-5p and correlates with adverse outcome in acute myeloid leukemia. Haematologica 2013;98:913-917.
15. Dzikiewicz-Krawczyk A, Macieja A, Maly E, Januszkiewicz-Lewandowska D, Mosor M, Fichna M, Strauss E, Nowak J: Polymorphisms in microRNA target sites modulate risk of lymphoblastic and myeloid leukemias and affect microRNA binding. J Hematol Oncol 2014;7:43.
16. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, Crowell RE, Patel R, Kulkarni T, Homer R, Zelterman D, Kidd KK, Zhu Y, Christiani DC, Belinsky SA, Slack FJ, Weidhaas JB: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res 2008;68:8535-8540.
17. Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P, Vodickova L, Novotny J, Forsti A, Hemminki K, Canzian F, Landi S: Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis 2008;29:579-584.
18. Yang H, Dinney CP, Ye Y, Zhu Y, Grossman HB, Wu X: Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res 2008;68:2530-2537.
19. Christensen BC, Moyer BJ, Avissar M, Ouellet LG, Plaza SL, McClean MD, Marsit CJ, Kelsey KT: A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers. Carcinogenesis 2009;30:1003-1007.
20. Jazdzewski K, Liyanarachchi S, Swierniak M, Pachucki J, Ringel MD, Jarzab B, de la Chapelle A: Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci U S A 2009;106:1502-1505.
21. Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, Shimizu M, Wojcik SE, Ferdin J, Kunej T, Xiao L, Manoukian S, Secreto G, Ravagnani F, Wang X, Radice P, Croce CM, Davuluri RV, Calin GA: Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res 2010;70:2789-2798.
22. Wang W, Li F, Mao Y, Zhou H, Sun J, Li R, Liu C, Chen W, Hua D, Zhang X: A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma. Hum Genet 2013;132:641-648.
23. Cui LH, Shin MH, Kweon SS, Kim HN, Song HR, Piao JM, Choi JS, Shim HJ, Hwang JE, Kim HR, Park YK, Kim SH: Methylenetetrahydrofolate reductase C677T polymorphism in patients with gastric and colorectal cancer in a Korean population. BMC Cancer 2010;10:236.
24. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7-9.
25. Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, Sun L, Ji G, Shi Y, Han Z, Han S, Nie Y, Chen X, Zhao Q, Ding J, Wu K, Daiming F: miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res 2011;9:824-833.
26. Yang TS, Yang XH, Wang XD, Wang YL, Zhou B, Song ZS: MiR-214 regulate gastric cancer cell proliferation, migration and invasion by targeting PTEN. Cancer Cell Int 2013;13:68.
27. Chen T, Huang Z, Wang L, Wang Y, Wu F, Meng S, Wang C: MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages. Cardiovasc Res 2009;83:131-139.
28. Frantzen F, Faaren AL, Alfheim I, Nordhei AK: Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem 1998;44:311-316.
29. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008;68:425-433.
30. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM: A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-833.
31. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-2261.
32. Flynt AS, Li N, Thatcher EJ, Solnica-Krezel L, Patton JG: Zebrafish miR-214 modulates Hedgehog signaling to specify muscle cell fate. Nat Genet 2007;39:259-263.
33. Zhang XJ, Ye H, Zeng CW, He B, Zhang H, Chen YQ: Dysregulation of miR-15a and miR-214 in human pancreatic cancer. J Hematol Oncol 2010;3:46.
34. Sanjoaquin MA, Allen N, Couto E, Roddam AW, Key TJ: Folate intake and colorectal cancer risk: A meta-analytical approach. Int J Cancer 2005;113:825-828.
35. Shrubsole MJ, Gao YT, Cai Q Shu XO, Dai Q Hebert JR, Jin F, Zheng W: MTHFR polymorphisms, dietary folate intake, and breast cancer risk: results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 2004;13:190-196.
36. Lee JE, Wei EK, Fuchs CS, Hunter DJ, Lee IM, Selhub J, Stampfer MJ, Willett WC, Ma J, Giovannucci E: Plasma folate, methylenetetrahydrofolate reductase (MTHFR), and colorectal cancer risk in three large nested case-control studies. Cancer Causes Control 2012;23:537-545.
37. Zintzaras E: Association of methylenetetrahydrofolate reductase (MTHFR) polymorphisms with genetic susceptibility to gastric cancer: A meta-analysis. J Hum Genet 2006;51:618-624.
38. Sun L, Sun YH, Wang B, Cao HY, Yu C: Methylenetetrahydrofolate reductase polymorphisms and susceptibility to gastric cancer in Chinese populations: A meta-analysis. Eur J Cancer Prev 2008;17:446-452.
39. Kim JK, Kim S, Han JH, Kim HJ, Chong SY, Hong SP, Hwang SG, Ahn JY, Cha KY, Oh D, Kim NK: Polymorphisms of 5,10-methylenetetrahydrofolate reductase and risk of stomach cancer in a Korean population. Anticancer Res 2005;25:2249-2252.
40. Vollset SE, Igland J, Jenab M, Fredriksen A, Meyer K, Eussen S, Gjessing HK, Ueland PM, Pera G, Sala N, Agudo A, Capella G, Del Giudice G, Palli D, Boeing H, Weikert C, Bueno-de-Mesquita HB, Carneiro F, Pala V, Vineis P, Tumino R, Panico S, Berglund G, Manjer J, Stenling R, Hallmans G, Martinez C, Dorronsoro M, Barricarte A, Navarro C, Quiros JR, Allen N, Key TJ, Bingham S, Linseisen J, Kaaks R, Overvad K, Tjonneland A, Buchner FL, Peeters PH, Numans ME, Clavel-Chapelon F, Boutron-Ruault MC, Trichopoulou A, Lund E, Slimani N, Ferrari P, Riboli E, Gonzalez CA: The association of gastric cancer risk with plasma folate, cobalamin, and methylenetetrahydrofolate reductase polymorphisms in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2007;16:2416-2424.
41. Zeybek U, Yaylim I, Yilmaz H, Agachan B, Ergen A, Arikan S, Bayrak S, Isbir T: Methylenetetrahydrofolate reductase C677T polymorphism in patients with gastric and colorectal cancer. Cell Biochem Funct 2007;25:419-422.
42. Galvan-Portillo MV, Cantoral A, Onate-Ocana LF, Chen J, Herrera-Goepfert R, Torres-Sanchez L, Hernandez-Ramirez RU, Palma-Coca O, Lopez-Carrillo L: Gastric cancer in relation to the intake of nutrients involved in one-carbon metabolism among MTHFR 677 TT carriers. Eur J Nutr 2009;48:269-276.
43. Zhu Y, Zhu RX, He ZY, Liu X, Liu HN: Association of MTHFR C677T with total homocysteine plasma levels and susceptibility to Parkinson's disease: A meta-analysis. Neurol Sci 2015;10.1007/s10072-014-2052-6
44. Zacho J, Yazdanyar S, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG: Hyperhomocysteinemia, methylenetetrahydrofolate reductase c.677C>T polymorphism and risk of cancer: cross-sectional and prospective studies and meta-analyses of 75,000 cases and 93,000 controls. Int J Cancer 2011;128:644-652.